A+ A A-

Download article

Sergiyevich A.V., Litvyakov A.M.
Clinical and laboratory peculiarities of patients with psoriatic arthritis
Education establishment "Vitebsk State Order of Peoples’ Friendship Medical University"

Psoriatic arthritis is chronic inflammatory azygomorphous oligoarthritis or polyarthritis with the involvement of the backbone which may occur together with psoriasis, or even may precede the appearance of  dermatitis characteristic of this disease. 58 persons with psoriatic arthritis were included in this research. The control group consisted of 26 healthy subjects. In persons with psoriatic arthritis the serumal level of arginase I, TNF-a, IL-1, and IL-6 was statistically significantly higher, than that in the control group; statistically significant moderate positive correlation between TNF- , IL-1, and IL-6 was found. Proatherogenic changes of lipide profile indices were determined. In the group of patients with psoriatic arthritis the presence of correlation between arginase I and the activity of an articular syndrome (DAS, index Ritchie), the severity of an integument lesion (PASI index); age and TC, TG, LDL-C, IA; HDL-C and indicators of the activity of an articular syndrome (index Ritchie, DAS28, DAS); LDL-C and duration of the disease was revealed.
Key words: psoriatic arthritis, arginase I, interleukins, lipids.


       1. Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum. 2004 Jan;50(1):24-35.
       2. Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, Dierssen T, Martin J, Gonzalez-Gay MA. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum. 2007 Aug;57(6):1074-80.
       3. Badokin VV, Korsakova YuL. Terapevticheskaia aktivnost' i bezopasnost' artrofoona pri psoriaticheskom artrite [Therapeutic activity and safety of treatment with artrofoon vs in psoriatic arthritis] [Elektronnyi resurs]. Consilium Medicum. 2006;(8). Rezhim dostupa: Data dostupa: 27.03.2014.
       4. Saricaoglu H, Güllülü S, Bülbül Baskan E, Cordan J, Tunali S. Echocardiographic findings in subjects with psoriatic arthropathy. J Eur Acad Dermatol Venereol. 2003 Jul;17(4):414-7.
       5. Milosavljevic J, Lindqvist U, Elvin A. Ultrasound and Power Doppler evaluation of the hand and wrist in patients with psoriatic arthritis. Acta Radiol. 2005 Jul;46(4):374-85.
       6. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, Van Voorhees AS, Elmets CA, Leonardi CL, Beutner KR, Bhushan R, Menter A. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008 May;58(5):851-64.
       7. Kochergin NG, Kochergin SN, Smirnova LM. Itogi raboty Pervoi vsemirnoi konferentsii po psoriazu i psoriaticheskomu artritu [Results of the First World Conference on psoriasis and psoriatic arthritis] [Elektronnyi resurs]. Russkii meditsinskii zhurnal. 2006. Rezhim dostupa: Data dostupa: 03.04.2014.
       8. Chang YT, Chou CT, Yu CW, Lin MW, Shiao YM, Chen CC, Huang CH, Lee DD, Liu HN, Wang WJ, Tsai SF. Cytokine gene polymorphisms in Chinese patients with psoriasis. Br J Dermatol. 2007 May;156(5):899-905.
       9. Teoli M, Zangrilli A, Chimenti MS, Talamonti M, Bavetta M, Graceffa D, Perricone R, Chimenti S. Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study. Clinical and Developmental Immunology [Electronic resource]. 2012. Mode of access: Date of access: 01.04.2014.
       10. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat. 2008;19(1):5-21.
       11. Freeston JE, Coates LC, Nam JL, Moverley AR, Hensor EM, Wakefield RJ, Emery P, Helliwell PS, Conaghan PG. Is there subclinical synovitis in early psoriatic arthritis? A clinical comparison with gray-scale and power Doppler ultrasound. Arthritis Care Res (Hoboken). 2014 Mar;66(3):432-9.
       12. Gottlieb AB, Antoni CE. Treating psoriatic arthritis: how effective are TNF antagonists? Arthritis Res Ther. 2004;6 Suppl 2:S31-5.
       13. Galluzzo E, Lischi DM, Taglione E, Lombardini F, Pasero G, Perri G, Riente L. Sonographic analysis of the ankle in patients with psoriatic arthritis. Scand J Rheumatol. 2000;29(1):52-5.
       14. Girolomoni G, Gisondi P. Psoriasis and systemic inflammation: underdiagnosed enthesopathy. Journal of the European Academy of Dermatology and Venereology. 2009 Sep;23 Suppl 1:3-8.
       15. Papoutsaki M, Osório F, Morais P, Torres T, Magina S, Chimenti S, Costanzo A. Infliximab in psoriasis and psoriatic arthritis. BioDrugs. 2013 Jan;27 Suppl 1:13-23.
       16. Chizhov NN. Psoriaticheskaia artropatiia [Psoriatic arthropathy] [Elektronnyi resurs]. Russkii meditsinskii server. Rezhim dostupa: Data dostupa: 29.03.2014.
       17. Bakewell CJ, Olivieri I, Aydin SZ, Dejaco C, Ikeda K, Gutierrez M, Terslev L, Thiele R, D'Agostino MA, Kaeley Gs. Ultrasound and magnetic resonance imaging in the evaluation of psoriatic dactylitis: status and perspectives. J Rheumatol. 2013 Dec;40(12):1951-7.
       18. Pietrzak A, Michalak-Stoma A, Chodorowska G, Szepietowski JC. Lipid disturbances in psoriasis: an update. Mediators of Inflammation [Electronic resource]. 2010. Mode of access: Date of access: 01.04.2014.
       19. Spadaro A, Montepaone M, Lubrano E. A novel biological target for the treatment of psoriatic arthritis. Immunotherapy. 2014 May;6(5):515-8.
       20. Muhr P, Zeitvogel J, Heitland I, Werfel T, Wittmann M. Expression of interleukin IL-1 family members upon stimulation with IL-17 differs in keratinocytes derived from patients with psoriasis and healthy donors. Br J Dermatol. 2011 Jul;165(1):189-93.
       21. Balato N, Di Costanzo L, Ayala F, Balato A, Sanduzzi A, Bocchino M. Psoriatic disease and tuberculosis nowadays. Clinical and Developmental Immunology [Electronic resource]. 2012. Mode of access: Date of access: 01.04.2014.
       22. Alsufyani MA, Golant AK, Lebwohl M. Psoriasis and the metabolic syndrome. Dermatol Ther. 2010 Mar-Apr;23(2):137-43.
       23. Ramonda R, Puato M, Punzi L, Rattazzi M, Zanon Marta, Balbi G, Ortolan A, Frallonardo P, Faggin E, Plebani M, Zaninotto M, Lorenzin M, Pauletto P, Doria A. Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: A two-year prospective observational study. Joint, Bone, Spine [Electronic resource]. 2014. Mode of access: Date of access: 10.04.2014.
       24. Campanati A, Orciani M, Consales V, Lazzarini R, Ganzetti G, Di Benedetto G, Di Primio R, Offidani A. Characterization and profiling of immunomodulatory genes in resident mesenchymal stem cells reflect the Th1-Th17/Th2 imbalance of psoriasis. Archives Of Dermatological Research [Electronic resource]. 2014. Mode of access: Date of access: 07.09.2014.
       25. Baran W, Szepietowski JC, Mazur G, Baran E. IL-6 and IL-10 promoteir gene polymorphiisms in psoriasis vulgaris. Acta Derm Venereol. 2008;88(2):113-6.
       26. Borska L, Fiala Z, Krejsek J, Andrys C, Vokurkova D, Hamakova K, Kremlacek J, Ettler K. Immunologic changes in TNF-alpha, sE-selectin, sP-selectin, sICAM-1, and IL-8 in pediatric patients treated for psoriasis with the Goeckerman regimen. Pediatr Dermatol. 2007 Nov-Dec;24(6):607-12.
       27. Tobin AM, Kirby B. TNFa inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs. 2005;19(1):47-57.
       28. Morken T, Bohov P, Skorve J, Ulvik R, Aukrust P, Berge RK, Livden JK. Anti-inflammatory and hypolipidemic effects of the modified fatty acid tetradecylthioacetic acid in psoriasis – a pilot study. Scand J Clin Lab Invest. 2011 Jul;71(4):269-73.
       29. Peluso R, Cafaro G, Di Minno A, Iervolino S, Ambrosino P, Lupoli G, Di Minno MN. Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies. Clin Rheumatol. 2013 Jun;32(6):743-53.
       30. Derer A, Groetsch B, Harre U, Böhm C, Towne J, Schett G, Frey S, Hueber AJ. Blockade of IL-36 Receptor Signaling Does Not Prevent from TNF-Induced Arthritis. Plos One [Electronic resource]. 2014;9(8). Mode of access: Date of access: 07.09.2014.
       31. Frey S, Derer A, Messbacher ME, Baeten DL, Bugatti S, Montecucco C, Schett G, Hueber AJ. The novel cytokine interleukin-36α is expressed in psoriatic and rheumatoid arthritis synovium. Ann Rheum Dis. 2013 Sep;72(9):1569-74.
       32. Ekman AK, Verma D, Fredrikson M, Bivik C, Enerbäck C. Genetic susceptibility of NLRP1 in psoriasis. Br J Dermatol. 2014 Dec;171(6):1517-20.
       33. Witte E, Kokolakis G, Witte K, Philipp S, Doecke WD, Babel N, Wittig BM, Warszawska K, Kurek A, Erdmann-Keding M, Kunz S, Asadullah K, Kadin ME, Volk HD, Sterry W, Wolk K, Sabat R. IL-19 is a Component of the Pathogenetic IL-23/IL-17 Cascade in Psoriasis. The Journal Of Investigative Dermatology [Electronic resource]. 2014 Nov;134(11). Mode of access: Date of access: 07.09.2014.
       34. Bech R, Otkjaer K, Birkelund S, Vorup-Jensen T, Agger R, Johansen C, Iversen L, Kragballe K, Rømer J. Interleukin 20 protein locates to distinct mononuclear cells in psoriatic skin. Exp Dermatol. 2014 May;23(5):349-52.
       35. Namazi MR. Possible molecular mechanisms to account for the involvement of tryptase in the pathogenesis of psoriasis. Autoimmunity. 2005 Sep;38(6):449-52.
       36. Zhang W, Baban B, Rojas M, Tofigh S, Virmani SK, Patel C, Behzadian MA, Romero MJ, Caldwell RW, Caldwell RB. Arginase activity mediates retinal inflammation in endotoxin-induced uveitis. Am J Pathol. 2009 Aug;175(2):891-902.
       37. Santhanam L, Christianson DW, Nyhan D, Berkowitz DE. Arginase and vascular aging. J Appl Physiol (1985). 2008 Nov;105(5):1632-42.
       38. Durante W, Johnson FK, Johnson RA. Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol. 2007 Sep;34(9):906-11.
       39. Tratsiakovich Y, Yanga J, Gononb AT, Sjöquista P-O, Pernow J. Arginase as a target for treatment of myocardial ischemia-reperfusion injury. European Journal Of Pharmacology. 2013;720(1-3):121–3.
       40. Durante W. Role of arginase in vessel wall remodeling. Frontiers In Immunology [Electronic resource]. 2013;4. Mode of access: Date of access: 05.04.2014.
       41. Abeyakirthi S, Mowbray M, Bredenkamp N, van Overloop L, Declercq L, Davis PJ, Matsui MS, Weller RB. Arginase is overactive in psoriatic skin. Br J Dermatol. 2010 Jul;163(1):193-6.
       42. Lai Y-L, Aoyama S, Nagai R, Miyoshi N, Ohshima1 H. Inhibition of L-arginine metabolizing enzymes by l-arginine-derived advanced glycation end products. J Clin Biochem Nutr. 2010 Mar; 46(2): 177–185.
       43. Morris SM. Recent advances in arginine metabolism: roles and regulation of the arginases. Br J Pharmacol. 2009 Jul;157(6):922-30.
       44. Ryoo S, Gupta G, Benjo A, Lim HK, Camara A, Sikka G, Lim HK, Sohi J, Santhanam L, Soucy K, Tuday E, Baraban E, Ilies M, Gerstenblith G, Nyhan D, Shoukas A, Christianson DW, Alp NJ, Champion HC, Huso D, Berkowitz DE. Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ Res. 2008 Apr;102(8):923-32.
       45. El-Mongy S, Fathy H, Abdelaziz A, Omran E, George S, Neseem N, El-Nour N. Subclinical atherosclerosis in patients with chronic psoriasis: a potential association. J Eur Acad Dermatol Venereol. 2010 Jun;24(6):661-6.
       46. Gupta M, Chari S, Borkar M, Chandankhede M. Dyslipidemia and oxidative stress in patients of psoriasis. Biomedical Research. 2011;22(2):221-4.
       47. Wu S, Li WQ, Han J, Sun Q, Qureshi AA. Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women. Arthritis Rheumatol. 2014 Feb;66(2):304-10.
       48. Antoniou C, Dessinioti C, Katsambas A, Stratigos AJ. Elevated triglyceride and cholesterol levels after intravenous antitumour necrosis factor-a therapy in a patient with psoriatic arthritis and psoriasis vulgaris. Br J Dermatol. 2007 May;156(5):1090-1.
       49. Goldminz AM, Buzney CD, Kim N, Au SC, Levine DE, Wang AC, Volf EM, Yaniv SS, Kerensky TA, Bhandarkar M, Dumont NM, Lizzul PF, Loo DS, Kulig JW, Brown ME, Lopez-Benitez JM, Miller LC, Gottlieb AB. Prevalence of the metabolic syndrome in children with psoriatic disease. Pediatr Dermatol. 2013 Nov-Dec;30(6):700-5.
       50. Papagoras C, Markatseli TE, Saougou I, Alamanos Y, Zikou AK, Voulgari PV, Kiortsis DN, Drosos AA. Cardiovascular risk profile in patients with spondyloarthritis. Joint Bone Spine. 2014 Jan;81(1):57-63.
       51. Robati RM, Partovi-Kia M, Haghighatkhah HR, Younespour S, Abdollahimajd F. Increased serum leptin and resistin levels and increased carotid intima-media wall thickness in patients with psoriasis: Is psoriasis associated with atherosclerosis? Journal Of The American Academy Of Dermatology [Electronic resource]. 2014. Mode of access: Date of access: 08.09.2014.
       52. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006 Aug;54(8):2665-73.
       53. Nasonov EL, Korotaeva TV. Rekomendatsii po lecheniiu psoriaticheskogo artrita [Guidelines for the treatment of psoriatic arthritis] [Elektronnyi resurs]. Nauchno-issledovatel'skii institut travmatologii im VA Nasonovoi: [sait]. Rezhim dostupa: Data dostupa: 01.12.14.
       54. Litvinov AV, red. Normy v meditsinskoi praktike [Standards in medical practice]: spravochnoe posobie. Moscow, RF: MEDpress; 2012. 144 р.
       55. Lipoproteiny [Lipoproteins] [Elektronnyi resurs]. Laboratorii Kieva i Ukrainy: [sait]. Rezhim dostupa: Data dostupa: 29.03.2014.
       56. Mastroianni A, Minutilli E, Mussi A, Bordignon V, Trento E, D'Agosto G, Cordiali-Fei P, Berardesca E. Cytokine profiles during infliximab monotherapy in psoriatic arthritis. Br J Dermatol. 2005 Sep;153(3):531-6.
       57. Viguier M, Guigue P, Pagès C, Smahi A, Bachelez H. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations. Ann Intern Med. 2010 Jul;153(1):66-7.
       58. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-a, IFN-y, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005 Oct;2005(5):273-9.


Поиск по сайту